SCHEMBL1242544

SCHEMBL1242544

CCOC(=O)c1cc2scnc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.59
MMP13 P45452 5/20 0.45
RAB9A P51151 5/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 4/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HSD17B10 Q99714 2/20 0.44
LMNA P02545 4/20 0.43
NPC1 O15118 3/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
MMP2 P08253 4/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332001 0.84 DAO (0.67) DAOKDM4EGLAGAA
SCHEMBL30112870 0.84 DAO (0.55) DAOMMP13RAB9AALDH1A1HPGD
SCHEMBL20745436 0.78 RAB9A (0.47) MMP13RAB9AALDH1A1HPGDKDM4E
SCHEMBL1242490 0.78 DAO (0.60) DAOMMP13RAB9AALDH1A1HPGD
SCHEMBL10077323 0.77 RAB9A (0.55) MMP13RAB9AALDH1A1HPGDKDM4E
SCHEMBL13395561 0.77 RAB9A (0.55) MMP13RAB9AALDH1A1HPGDKDM4E
SCHEMBL24702448 0.77 DAO (0.71) DAORAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL20745602 0.77 RAB9A (0.46) MMP13RAB9AALDH1A1HPGDKDM4E
SCHEMBL13395562 0.76 KDM4E (0.49) MMP13RAB9AALDH1A1HPGDKDM4E
SCHEMBL30861733 0.75 ALOX15 (0.52) MMP13RAB9AALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2026-01-08 US disclosed
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-20250144093-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2025-05-08 US disclosed
EP-4536350-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2025-04-16 EP disclosed
US-20240391932-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2024-11-28 US disclosed
US-12133853-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-11-05 US disclosed
EP-4401739-A1 COMPOUNDS, COMPOSITIONS AND METHODS Nico Therapeutics, Inc. (US) 2024-07-24 EP disclosed
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20070299112-A1 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMACEUTICAL INC. (US) 2007-12-27 US disclosed
US-20070299112-A1 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMACEUTICAL INC. (US) 2007-12-27 US disclosed
US-20070299112-A1 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I AVENTIS PHARMACEUTICAL INC. (US) 2007-12-27 US disclosed
EP-1784409-A2 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON Aventis Pharmaceuticals, Inc. (US) 2007-05-16 EP disclosed
WO-2006021000-A2 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON AVENTIS PHARMACEUTICALS INC. (US) 2006-02-23 WO disclosed
US-6479527-B1 Bicyclic pyrrole derivatives as MCP-1 inhibitors ASTRAZENECA UK LIMITED (GB) 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872225-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 DAO 3564/4885MMP13 4055/4885RAB9A 3629/4885
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase DAO, DDO, AOX1 DAO 1/4885MMP13 2104/4885RAB9A 2860/4885
US-20070299112-A1 SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I CSNK1A1, CSNK1E, CSNK2A1 DAO 553/4885MMP13 3565/4885RAB9A 2583/4885
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 DAO 2921/4885MMP13 1620/4885RAB9A 872/4885
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 DAO 2921/4885MMP13 1620/4885RAB9A 872/4885
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NOD1, NLRP3, CASP1 DAO 1879/4885MMP13 3530/4885RAB9A 2451/4885
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 DAO 1977/4885MMP13 3275/4885RAB9A 3006/4885
US-12133853-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 DAO 2111/4885MMP13 3126/4885RAB9A 1955/4885
US-20240391932-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 DAO 3739/4885MMP13 3007/4885RAB9A 1755/4885
US-20250144093-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 DAO 2111/4885MMP13 3126/4885RAB9A 1955/4885
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE DAO, DDO, AOX1 DAO 1/4885MMP13 3050/4885RAB9A 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.